All News
SARD-ILD: Significant diagnostic and treatment delays
Should we be screening all our patients with systemic autoimmune rheumatic disease (SARD) for interstitial lung disease? I have been asking myself that question after the recent publication of American Thoracic Society Interstitial Lung Disease screening guidelines. The ATS guidelines, which were published in May, recommend universal CT chest screening for all asymptomatic patients with RA, systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, and Sjögren’s disease.
Read Article
When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD
When idiopathic inflammatory myopathies (IIM) affect the lungs, the consequences can be serious. ILD is not only common in IIM, but also one of the leading causes of death, contributing to up to 80% of mortality in this patient group. For rheumatologists, two subsets stand out: anti-synthetase syndrome (ASyS) and anti-MDA-5 positive dermatomyositis (MDA5-DM). These patients present with distinct clinical clues, very different disease trajectories, and unique treatment challenges. Recognizing ILD early and acting decisively can make the difference between stabilizing a chronic course and facing a rapidly progressive, often fatal decline.
Read Article
Patient Resource: The Hidden Connection - ILD and Rheumatic Disease
Dr. Iazsmin Bauer Ventura, Chicago, talks about ILD as a window to systemic disease as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/8rJm4O3hHU
Dr. John Cush RheumNow ( View Tweet)
RA-associated interstitial lung disease or bronchiectasis is assoc w/ increased risk of total and cause-specific mortality. retrospective cohort study using the Mass General Brigham Biobank 221 RA-LD cases (151 RA-ILD, 70 RA-BR). RA-LD higher mortality (34 vs 13/1000PY; HR
Dr. John Cush RheumNow ( View Tweet)
When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD
When idiopathic inflammatory myopathies (IIM) affect the lungs, the consequences can be serious. Interstitial lung disease (ILD) is not only common in IIM, but also one of the leading causes of death, https://t.co/qRoTr3r84x
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 201 IPAF (Interstitial pneumonia w/ autoimmune feat.) pts w/ F/U 5.6 yrs. ANA+ 80%, RF+ 25%, CCP+ 14%, 88% Rx w/ IS or antifibrotics. 24% died, 7.5% transplant. Comorbidies were common; mean CCI 3.2; IPAF mortality worsened by
Dr. John Cush RheumNow ( View Tweet)
🆕 ILD (Part II): advanced insights
🫁 Multidisciplinary management
💊 Treatment strategies
📊 Prognosis & monitoring
🧑⚕️ What rheums should know next
⬇️ Download & learn more: https://t.co/dmhULfqiMj
Created by
@MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/ivvDjxkCvt
Dr. John Cush RheumNow ( View Tweet)
Non-Pharmacologic ILD Care
Jon T. Giles, MD, MPH, discusses non-Pharmacologic approaches to ILD treatment and patient care. Sponsored By: Boehringer Ingelheim
https://t.co/Mxg9P50m7C
#ILD #Rheumatology https://t.co/5wD1K7J1Gq
Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Beyond the Numbers in Newly Diagnosed ILD
Dr. Eric Dein, Summit, NJ, presents a case of a new patient with interstitial lung disease, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025.
https://t.co/HLnX5WbbTw https://t.co/SZeI4bqSAm
Dr. John Cush RheumNow ( View Tweet)
How to assess ILD in your patients?
Have a high index of suspicion in your patients with connective tissue disease (especially systemic sclerosis, inflammatory myositis), and rheumatoid arthritis. All patients with CTD may develop ILD but it is more common (% of patients with https://t.co/UXdvPJCqDi
Dr. John Cush RheumNow ( View Tweet)
PsO/PsA patients have an ⬆️ CV risk brought about by traditional and CV risk factors.
Do you perform regular CV risk screening in your patients?
@RheumNow #APLAR25 https://t.co/BGNKrKeLsI
sheila RHEUMarampa ( View Tweet)
Target trial emulation looked at CV (MACE) events in 18,120 propensity score–matched adults with gout starting allopurinol who were given NSAIDs or colchicine for prophylaxis. MACE & CV death were signif. higher w/ NSAIDs vs Colchicine (HRs of 1.56 and 2.50), respectively. https://t.co/0T8slmPBng
Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Progressive RA-ILD Management
Dr. Richard Conway, a rheumatologist in Dublin, discusses a case about managing progressive rheumatoid arthritis-interstitial lung disease, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September https://t.co/dLCXeXwl7w
Dr. John Cush RheumNow ( View Tweet)
How to treat CTD ILD?
A comparative slide summarizing ACR/BSR and EULAR treatment guidelines
Emphasis on combination of Immunosuppressant and Antifibrotics
@RheumNow #APLAR25 https://t.co/gLSht6QKh5
Aurelie Najm AurelieRheumo ( View Tweet)
A framework for treatment stratified approach in CTD-ILD, by Dr Low Hsiu Ling
Based on
-ILD extent
-Risk of progression
-Biology: fibrosis/inflammation
-Safety
-Other manifestations
@RheumNow #APLAR25 https://t.co/ma5KugzBHy
Aurelie Najm AurelieRheumo ( View Tweet)
Why shall we screen all patients with SSc for ILD?
Focusing screening strategy on patients « at risk » misses 25% of patients with ILD
ILD being the main cause of mortality in SSc
@RheumNow #APLAR25 https://t.co/djzCTdZoVb
Aurelie Najm AurelieRheumo ( View Tweet)
Peter Taylor on extra articular manifestations of RA
Keep an eye on RA patients’ glomerular function
RA patients have increased risk of CKD
Systematic review >1million pts
Risk Ratio 1.52
@RheumNow #APLAR25 https://t.co/5iZwtmvwSR
Aurelie Najm AurelieRheumo ( View Tweet)
🆕 Intro to ILD (Part I): the essentials
🫁 Definition & basics
🔬 Key pathology patterns
🧑⚕️ Clinical approach
📋 What rheums need to know
⬇️ Download & learn more: https://t.co/7RzpTDOjwa
Created by @MithuRheum | via @RheumNow for our Rheum to Breathe: ILD Campaign https://t.co/D9d97bqcD5
Dr. John Cush RheumNow ( View Tweet)
PAH diagnosis and management in the context of CTD ILD
Pulmonary arterial hypertension (PAH) is a serious complication of connective tissue disorders (CTD), affecting about 25% of PAH patients. CTD-PAH is the second most common cause after the idiopathic form. PAH involves high https://t.co/UgsdYWv02S
Dr. John Cush RheumNow ( View Tweet)
QD Clinic Video: RA and Bronchiectasis
Dr. Jeffrey Sparks, Boston, talks about rheumatoid arthritis and bronchiectasis as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025.
https://t.co/Y2u3m4rFfj https://t.co/KgrIxXlQo4
Dr. John Cush RheumNow ( View Tweet)
